Apollo Endosurgery, Inc. (NASDAQ: APEN), shares dropped -4.28% to 3.800 in the early morning today as the global leader in minimally invasive surgical methods announced that the X-Tack Endoscopic HeliX Tacking System had received 510(k) clearance from the U.S. Food & Drug Administration.
The X-Tack is a brand new through-the-scope, a suture-based device designed specifically to treat gastrointestinal problems in the lower gastrointestinal tract with applications in the upper gastrointestinal tract.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
X-Tack allows physicians to solve challenges commonly encountered when closing irregularly shaped or large defects. This procedure involves suture-tethered HeliX tacks, positioned independently in adjacent healthy tissue, and are then cinched to close the construct. The X-Tack system answers a long-expressed need for advanced closure devices to improve healing and prevent adverse events after colonic polypectomy and mucosal resections, such as delayed bleeding or perforation.
A limited launch with gastroenterologists will be initiated in January 2021 to be followed by a full launch late in the first quarter of 2021.
